AtriCure (ATRC) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free ATRC Stock Alerts $22.67 -0.52 (-2.24%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 1:33 AM | marketbeat.comAtriCure, Inc. (NASDAQ:ATRC) Given Consensus Recommendation of "Buy" by BrokeragesAtriCure, Inc. (NASDAQ:ATRC - Get Free Report) has been given an average rating of "Buy" by the seven ratings firms that are covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts tMay 24, 2024 | marketbeat.comAtriCure, Inc. (NASDAQ:ATRC) Shares Bought by Trexquant Investment LPTrexquant Investment LP lifted its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 202.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,193 shares of the medical device company's stock after purchasingMay 22, 2024 | marketbeat.comGW&K Investment Management LLC Sells 61,418 Shares of AtriCure, Inc. (NASDAQ:ATRC)GW&K Investment Management LLC trimmed its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 805,109 shares of the medical deviceMay 21, 2024 | marketbeat.comBNP Paribas Asset Management Holding S.A. Has $16.30 Million Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)BNP Paribas Asset Management Holding S.A. lowered its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 456,762 shares of the medical deMay 20, 2024 | marketbeat.com87,100 Shares in AtriCure, Inc. (NASDAQ:ATRC) Purchased by Bridger Management LLCBridger Management LLC bought a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 87,100 shares of the medical device company's stock, valued at approximately $May 18, 2024 | marketbeat.comPanagora Asset Management Inc. Purchases 63,079 Shares of AtriCure, Inc. (NASDAQ:ATRC)Panagora Asset Management Inc. lifted its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 38.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 229,197 shares of the medical device company's stock after buMay 16, 2024 | marketbeat.comAtriCure, Inc. (NASDAQ:ATRC) Short Interest Down 6.9% in AprilAtriCure, Inc. (NASDAQ:ATRC - Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 2,980,000 shares, a decline of 6.9% from the April 15th total of 3,200,000 shares. Based on an average daily volume of 789,000 shares, the short-interest ratio is currently 3.8 days.May 15, 2024 | businesswire.comAtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads ConferenceMay 9, 2024 | marketbeat.comTimesSquare Capital Management LLC Purchases 71,275 Shares of AtriCure, Inc. (NASDAQ:ATRC)TimesSquare Capital Management LLC increased its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 7.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 976,110 shares of the medical device company's stocMay 6, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Stock Price Up 6.7%AtriCure (NASDAQ:ATRC) Shares Up 6.7%May 4, 2024 | finance.yahoo.comAtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price TargetMay 4, 2024 | insidertrades.comAtriCure, Inc. (NASDAQ:ATRC) Insider Sells $36,135.00 in StockMay 3, 2024 | markets.businessinsider.comAtricure’s Strong Performance and Growth Potential Affirm Buy RatingMay 3, 2024 | marketbeat.comAtriCure, Inc. (NASDAQ:ATRC) Insider Justin J. Noznesky Sells 1,500 SharesAtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Justin J. Noznesky sold 1,500 shares of AtriCure stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $24.09, for a total transaction of $36,135.00. Following the completion of the transaction, the insider now directly owns 71,284 shares in the company, valued at $1,717,231.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.May 3, 2024 | finance.yahoo.comAtriCure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 3, 2024 | finance.yahoo.comThe past three years for AtriCure (NASDAQ:ATRC) investors has not been profitableMay 2, 2024 | markets.businessinsider.comAtricure’s Growth and Resilience Reinforce Buy RatingMay 2, 2024 | finance.yahoo.comAtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call TranscriptMay 2, 2024 | marketbeat.comCanaccord Genuity Group Cuts AtriCure (NASDAQ:ATRC) Price Target to $49.00Canaccord Genuity Group dropped their price target on AtriCure from $57.00 to $49.00 and set a "buy" rating for the company in a research note on Thursday.May 2, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPSAtriCure (NASDAQ:ATRC - Get Free Report) released its quarterly earnings results on Wednesday. The medical device company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.02). The business had revenue of $108.90 million for the quarter, compared to the consensus estimate of $106.86 million. AtriCure had a negative net margin of 7.62% and a negative return on equity of 7.55%. The firm's revenue for the quarter was up 16.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.23) EPS.May 2, 2024 | markets.businessinsider.comAtriCure’s Strong Growth and Market Position Justify Buy RatingMay 2, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Hits New 1-Year Low on Analyst DowngradeAtriCure (NASDAQ:ATRC) Hits New 52-Week Low on Analyst DowngradeMay 2, 2024 | finance.yahoo.comAtriCure Inc (ATRC) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 1, 2024 | investorplace.comATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Releases FY 2024 Earnings GuidanceAtriCure (NASDAQ:ATRC) updated its FY 2024 earnings guidance. The company provided EPS guidance of -0.820--0.740 for the period, compared to the consensus estimate of -0.740. The company also issued revenue guidance of $459.0 millionillion-$466.0 millionillion, compared to the consensus estimate of $461.3 millionillion.May 1, 2024 | finance.yahoo.comAtriCure Inc (ATRC) Surpasses Revenue Estimates in Q1 2024 Despite Wider LossesMay 1, 2024 | businesswire.comAtriCure Reports First Quarter 2024 Financial ResultsApril 30, 2024 | markets.businessinsider.comAtriCure is about to announce its earnings — here's what Wall Street expectsApril 30, 2024 | businesswire.comAtriCure to Participate in the 2024 Bank of America Securities Healthcare ConferenceApril 23, 2024 | msn.comAtriCure upgraded at Oppenheimer on valuationApril 23, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Upgraded at OppenheimerOppenheimer upgraded shares of AtriCure from a "market perform" rating to an "outperform" rating and set a $32.00 target price on the stock in a report on Tuesday.April 22, 2024 | finance.yahoo.comAtriCure, Inc. (ATRC) Stock Price, News, Quote & History - Yahoo FinanceApril 22, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Reaches New 1-Year Low at $22.36AtriCure (NASDAQ:ATRC) Reaches New 12-Month Low at $22.36April 20, 2024 | nasdaq.comFirst Week of June 21st Options Trading For AtriCure (ATRC)April 20, 2024 | investing.comAtriCure launches advanced cryoablation probe to expedite surgeriesApril 20, 2024 | marketbeat.comAtriCure, Inc. (NASDAQ:ATRC) Shares Acquired by Knights of Columbus Asset Advisors LLCKnights of Columbus Asset Advisors LLC lifted its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 165.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 123,540 shares of the medical device companApril 18, 2024 | businesswire.comAtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain ManagementApril 17, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Trading 3.2% Higher AtriCure (NASDAQ:ATRC) Trading 3.2% HigherApril 16, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Reaches New 52-Week Low at $22.42AtriCure (NASDAQ:ATRC) Hits New 12-Month Low at $22.42April 15, 2024 | marketbeat.comShort Interest in AtriCure, Inc. (NASDAQ:ATRC) Expands By 9.4%AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,250,000 shares, a growth of 9.4% from the March 15th total of 2,970,000 shares. Based on an average daily volume of 668,700 shares, the days-to-cover ratio is presently 4.9 days.April 10, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Reaches New 12-Month Low at $25.76AtriCure (NASDAQ:ATRC) Reaches New 52-Week Low at $25.76April 10, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $46.00 price target on shares of AtriCure in a research note on Wednesday.April 10, 2024 | businesswire.comAtriCure to Announce First Quarter 2024 Financial ResultsApril 9, 2024 | marketbeat.comAtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of "Buy" from BrokeragesAtriCure, Inc. (NASDAQ:ATRC - Get Free Report) has been given a consensus recommendation of "Buy" by the five analysts that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price target amongApril 3, 2024 | marketbeat.comInsider Selling: AtriCure, Inc. (NASDAQ:ATRC) Insider Sells 1,500 Shares of StockAtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Justin J. Noznesky sold 1,500 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $30.39, for a total transaction of $45,585.00. Following the transaction, the insider now owns 72,784 shares of the company's stock, valued at $2,211,905.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.April 2, 2024 | marketbeat.comAtriCure (NASDAQ:ATRC) Hits New 12-Month Low at $27.86AtriCure (NASDAQ:ATRC) Hits New 52-Week Low at $27.86March 31, 2024 | marketbeat.comVanguard Group Inc. Boosts Position in AtriCure, Inc. (NASDAQ:ATRC)Vanguard Group Inc. lifted its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 0.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,689,883 shares of the medical device company's stock afterMarch 30, 2024 | marketbeat.comAtriCure, Inc. (NASDAQ:ATRC) Short Interest Up 25.3% in MarchAtriCure, Inc. (NASDAQ:ATRC - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 2,970,000 shares, a growth of 25.3% from the February 29th total of 2,370,000 shares. Based on an average daily trading volume, of 618,100 shares, the days-to-cover ratio is currently 4.8 days.March 30, 2024 | marketbeat.comAtriCure, Inc. (NASDAQ:ATRC) Shares Bought by Assenagon Asset Management S.A.Assenagon Asset Management S.A. lifted its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 28.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 259,169 shares of the medical device compaMarch 28, 2024 | ca.finance.yahoo.comATRC May 2024 30.000 call Get AtriCure News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Email Address You won't believe what Citigroup just did to it's depositors (Ad)The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"... CLICK HERE TO GET YOUR GUIDE NOW ATRC Media Mentions By Week ATRC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRC News Sentiment▼1.830.79▲Average Medical News Sentiment ATRC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRC Articles This Week▼53▲ATRC Articles Average Week Get AtriCure News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ATEC News Today OFIX News Today SRDX News Today IART News Today CATX News Today AORT News Today MDXG News Today SILK News Today ATRI News Today EMBC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRC) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.